Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Myeloid 8Sarcoma 1NET 1Lymphoid 1Endocrine 1Classical hematology 1CNS 1Breast 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 69Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8Fluorodeoxyglucose F18 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × decitabine and cedazuridine drug combination × CNS × Clear all
NCT03922555 2026-04-16

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Massachusetts General Hospital

Phase 1 Recruiting
18 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡